The Food and Drug Administration's New Drug Application is the vehicle in the United States through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing. From Wikipedia
The decision marks the second rejection of the drug application, with Aldeyra planning a mid-2025 resubmission pending new trial results.
